Ikena Oncology Inc. (IKNA) NASDAQ
$1.32 0.03 (1.94%)
Market Cap: $62.25M
As of 04/25/24 11:03 AM EDT. Market open.
Ikena Oncology Inc. (IKNA)
NASDAQ
$1.32
0.03 (1.94%)
Market Cap: $62.25M
As of 04/25/24 11:03 AM EDT. Market open.
Add to Portfolio
ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
82
Address
.
PRICE CHART FOR IKENA ONCOLOGY INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.29
Previous Close
$1.29
Days Range
$1.28 - $1.39
52 week range
$1.02 - $7.64
Volume
56,390
Avg. Volume (30 days)
241,748
Market Cap
$62.25M
Dividend Yield
-
P/E
(0.91)
Shares Outstanding
48,258,111
Open
$1.29
Previous Close
$1.29
Days Range
$1.28 - $1.39
52 week range
$1.02 - $7.64
Volume
56,390
Avg. Volume (30 days)
241,748
Market Cap
$62.25M
Dividend Yield
-
P/E
(0.91)
Shares Outstanding
48,258,111
FINANCIAL STATEMENTS FOR IKENA ONCOLOGY INC
LOADING...
INSIDER TRANSACTIONS FOR IKENA ONCOLOGY INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
ORBIMED ADVISORS LLC | Director | Jun 24, 2022 | Buy | $4.96 | 162,000 | 803,975 | 2,098,097 | Jun 24, 2022, 05:39 PM |
ORBIMED ADVISORS LLC | Director | Jun 23, 2022 | Buy | $3.71 | 23,419 | 86,884 | 1,936,097 | Jun 24, 2022, 05:39 PM |
ORBIMED ADVISORS LLC | Director | Jun 22, 2022 | Buy | $3.55 | 66,806 | 237,161 | 1,912,678 | Jun 24, 2022, 05:39 PM |
Bonita David P | Director | Jun 22, 2022 | Buy | $3.55 | 66,806 | 237,161 | 1,912,678 | Jun 24, 2022, 05:32 PM |
Bonita David P | Director | Jun 24, 2022 | Buy | $4.96 | 162,000 | 803,975 | 2,098,097 | Jun 24, 2022, 05:32 PM |
Bonita David P | Director | Jun 23, 2022 | Buy | $3.71 | 23,419 | 86,884 | 1,936,097 | Jun 24, 2022, 05:32 PM |
Tessier Maude | Chief Business Officer | Jan 18, 2022 | Option Exercise | $3.54 | 71,786 | 253,800 | 100,578 | Jan 20, 2022, 04:30 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 10, 2022 | Option Exercise | $2.15 | 36 | 77 | 44,511 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 11, 2022 | Option Exercise | $2.15 | 964 | 2,069 | 45,439 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 10, 2022 | Sale | $12.00 | 36 | 432 | 44,475 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 11, 2022 | Sale | $12.00 | 964 | 11,568 | 44,475 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Dec 10, 2021 | Option Exercise | $2.15 | 1,000 | 2,146 | 45,475 | Dec 14, 2021, 08:48 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Dec 10, 2021 | Sale | $14.76 | 1,000 | 14,760 | 44,475 | Dec 14, 2021, 08:48 PM |
FORMELA JEAN FRANCOIS | Director | Mar 30, 2021 | Buy | $16.00 | 125,000 | 2,000,000 | 874,634 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 10, 2021 | Sale | $15.03 | 11,989 | 180,195 | 1,256,224 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 14, 2021 | Sale | $14.00 | 5,959 | 83,426 | 1,241,935 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 13, 2021 | Sale | $14.64 | 8,330 | 121,951 | 1,247,894 | Dec 14, 2021, 08:29 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Mar 30, 2021 | Buy | $16.00 | 125,000 | 2,000,000 | 874,634 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 14, 2021 | Sale | $14.00 | 5,959 | 83,426 | 1,241,935 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 13, 2021 | Sale | $14.64 | 8,330 | 121,951 | 1,247,894 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 10, 2021 | Sale | $15.03 | 11,989 | 180,195 | 1,256,224 | Dec 14, 2021, 08:27 PM |
Bonita David P | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 1,845,872 | Apr 14, 2021, 06:29 PM |
ORBIMED ADVISORS LLC | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 1,845,872 | Apr 13, 2021, 06:36 PM |
Stampacchia Otello | Director | Mar 30, 2021 | Option Exercise | $16.00 | 450,000 | 7,200,000 | 2,249,123 | Apr 01, 2021, 06:16 PM |
Bonita David P | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 2,191,425 | Apr 01, 2021, 06:14 PM |
ORBIMED ADVISORS LLC | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 2,191,425 | Apr 01, 2021, 06:13 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
FUNDS WITH A POSITION IN IKENA ONCOLOGY INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 12,048,773 | 0.73% | No change | Other |
ORBIMED ADVISORS LLC | 3,539,358 | 0.14% | 11.09% | Other |
BLACKROCK INC. | 1,858,156 | 0.00009% | 28.49% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 529,369 | 0.00011% | 2.35% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 287,900 | 0.00117% | -29.42% | Other |
CHANGE IN SHARES OUTSTANDING FOR IKENA ONCOLOGY INC
STOCK BUYBACKS FOR IKENA ONCOLOGY INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
10.21%
1Q
06/30/2023
21.84%
2Q
03/31/2023
32.04%
3Q
12/31/2022
32.03%
4Q
09/30/2022
32.04%
5Q
06/30/2022
32.39%
6Q
03/31/2022
32.70%
7Q
12/31/2021
71.08%
8Q
09/30/2021
33.50%
9Q
06/30/2021
33.53%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR IKENA ONCOLOGY INC
LOADING...